Innovation Health and Sanofi (NYSE:SNY) said today that the companies are launching a pilot program to evaluate the impact of digital health solutions from One Drop and Common Sensing for people with Type II diabetes.
The program hopes to enable pharmaceutical companies, tech companies and plan providers to work together to improve patient outcomes, according to Innovation Health.
“Creating unique relationships and implementing innovative care solutions is part of Innovation Health’s DNA,” Innovation Health’s CMO & chief medical informatics officer Dr. Sunil Budhrani said in prepared remarks. “As overall Type II diabetes diagnosis rates continue to rise, especially among children and teens, this pilot program will enable us to better understand, in adults 18 to 65 years old, how new technologies can help improve public health.”
The program is slated to assess technologies from One Drop and Common Sensing.
One Drop’s diabetes-management platform includes a Bluetooth-enabled blood glucose monitor, diabetes coaching and a mobile app. The technology measures and analyzes users blood glucose data, medication use, diet and physicial activity. Users can also reach their diabetes coach anytime using the in-app chat function.
Common Sensing’s Gocap clinical dashboard is designed to connect patients who are struggling with insulin use to their clinicians.
“As a leader in diabetes, our ambition is to empower people with diabetes to live the life they want,” Sanofi US DCV’s VP of Innovative Solutions, Sebastien Coisne, added.
“We believe that combining innovative medicines with connected devices and solutions leads to better patient outcomes and an improved patient experience. As innovative solutions come to market, we are very excited to work with Innovation Health on this pilot program and trust it will provide further insights to achieve that goal.”
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
